Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Slides:

Advertisements

Similar presentations

Elizabeth A. David, MD, David T

Advertisements

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Thomas J. Birdas, MD, Richard P. M

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Chun Chieh Lin, PhD, MBA, Matthew P

Joshua E. Rosen, BASc, Hari B

Ravi Rajaram, MD, MSc, Jennifer L

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Castigliano M. Bhamidipati, DO, MS, George J

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Adil Ayub, MD, Sadiq S. Rehmani, MD, Adnan M

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Surgical Treatment of Metachronous Second Primary Lung Cancer

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Anthony Lemaire, MD, William R

A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer Brian C. Gulack, MD, Chi-Fu Jeffrey Yang,

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases Haifeng Wang, MM, Hongsheng Lin, MM, Gening.

Total Arterial Revascularization: A Superior Strategy for Diabetic Patients Who Require Coronary Surgery James Tatoulis, MD, FRACS, Rochelle Wynne, PhD,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Comparison of the 6th and 7th Editions of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System in Patients With Resected Esophageal.

Michael Lanuti, MD, Pierre E

Alex K. Bryant, BS, Robert C. Mundt, HSDG, Ajay P. Sandhu, MD, James J

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Primary Cardiac Sarcoma

Acute Kidney Injury Increases Mortality After Lung Transplantation

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

Asvin M. Ganapathi, MD, Paul J. Speicher, MD, Anthony W

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Benny Weksler, MD, Manisha Shende, MD, Katie S

Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B

Mark W. Hennon, MD, Elisabeth U

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Thirty-Day Mortality Underestimates the Risk of Early Death After Major Resections for Thoracic Malignancies Robert R. McMillan, MD, MPH, Alexandra Berger,

Presentation transcript:

Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A. George, MS, Reshma Jagsi, MD, DPhil, Thomas A. D’Amico, MD, Elisabeth U. Dexter, MD, Fawn D. Vigneau, JD, MPH, Feng Ming Kong, MD, PhD The Annals of Thoracic Surgery Volume 104, Issue 6, Pages 1881-1888 (December 2017) DOI: 10.1016/j.athoracsur.2017.06.065 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Percent distribution of non-small cell lung cancer (NSCLC) staging as defined by the American Joint Committee on Cancer (AJCC) between the years 2000 and 2010. Histogram divided into early stage (I and II) disease in blue and late stage (III and IV) disease in red for ease of comparison. The Annals of Thoracic Surgery 2017 104, 1881-1888DOI: (10.1016/j.athoracsur.2017.06.065) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Distribution of definitive therapy for stage I non-small cell lung cancer (NSCLC) between 2000 and 2010. The proportion of patients undergoing surgery during this time span are represented in red. Patients treated with combined surgery and radiation therapy (RT) are represented in purple. Patients treated with RT only are represented in blue. Patients receiving neither RT nor surgery are represented in green. Patients with unknown treatment details are represented in black. The Annals of Thoracic Surgery 2017 104, 1881-1888DOI: (10.1016/j.athoracsur.2017.06.065) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Annual proportions of (A) all treatments and (B) types of surgery used to treat Stage I non-small cell lung cancer (NSCLC) between 2000 and 2010. For A, types of treatments include surgery (blue), combined surgery and radiation therapy (RT) (yellow), radiation therapy (green), or no treatment (red). Types of surgery in B include pneumonectomy (green), lobectomy (red), or sublobar resection (blue). The Annals of Thoracic Surgery 2017 104, 1881-1888DOI: (10.1016/j.athoracsur.2017.06.065) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Survival outcomes for stage I non-small cell lung cancer (NSCLC) by definitive treatment type, 2000 to 2010. Kaplan-Meier survival curves, in months, for the years 2000 (red), 2002 (orange), 2004 (yellow), 2006 (green), 2008 (blue), and 2010 (purple) in (A) all patients, (B) patients receiving radiation therapy only, and (C) patients receiving surgery only. The Annals of Thoracic Surgery 2017 104, 1881-1888DOI: (10.1016/j.athoracsur.2017.06.065) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions